If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGenedrive Regulatory News (GDR)

Share Price Information for Genedrive (GDR)

Share Price is delayed by 15 minutes
Get Live Data
1.275    -0.025 (-1.92%)
Bid:
1.25
Ask:
1.30
Spread: 0.05 (4.00%)
Market Cap: £20.47m
GDR Live PriceLast checked at - London Stock Exchange

Intraday Genedrive Share Chart

Board appointment

17 Mar 2022 07:00

RNS Number : 0274F
Genedrive PLC
17 March 2022
 

genedrive plc

("genedrive" or the "Company")

 

Board appointment

 

genedrive plc (AIM: GDR), the near patient molecular diagnostics company announces the appointment of Russell ("Russ") Shaw as the Group's Chief Financial Officer ("CFO") and a Director of the Company with effect from 7 April 2022.

 

Russell joins genedrive with over 16 years' experience in senior positions in the industrials, technology and business services industries. Prior to joining genedrive, Russell spent 10 years as Finance Director at Driver Group plc, an AIM quoted company providing consultancy services to the engineering and construction industries. Russell has been CFO of several private companies in recent years and currently holds this position at Inflow Consultancy Limited from which he will resign prior to joining the Board of genedrive. Russell is a fellow of the Chartered Institute of Management Accountants.

 

Russell will join the Company as an employee on 23 March 2022 to ensure there is a handover period with the outgoing CFO, Matthew Fowler, who will now be resigning from the Board on 7 April 2022 rather than 19 April 2022 as previously stated.

 

Commenting on the appointment, David Budd, Chief Executive Officer of Genedrive, said: "Russ' experience will allow him to have a positive impact across the Company, both at an operational and strategic level. I am very pleased to have Russ join genedrive and look forward to his contributions and input in the commercial and financial growth of the Company. At the same time, we would like to thank Matthew Fowler for his work and diligence as CFO over the past five years and wish him every success in his next role."

 

Russell Shaw, incoming Chief Financial Officer of Genedrive, said: "I'm excited to be joining genedrive at this stage of development. I am looking forward to working with the Board and the entire operational team to seize opportunities and build on the strengths of the business."

 

The following information is disclosed pursuant to Schedule Two, paragraph (g) of the AIM Rules for Companies:

 

Full name and age: Russell John Shaw (aged 43)

 

Russell Shaw does not currently hold any shares in genedrive plc.

 

Current Directorships or Partnerships: Inflow Consultancy Limited

 

Past Directorships of Partnerships: I4 Technology Group Limited, Edge Worldwide Logistics Limited

 

No further information in connection with his appointment is required to be disclosed under Schedule Two, paragraph (g) of the Aim Rules for Companies.

 

 

For further details please contact:

genedrive plc

David Budd: CEO

+44 (0)161 989 0245

Peel Hunt LLP (Nominated Adviser and Joint Broker)

+44 (0)20 7418 8900

James Steel

finnCap (Joint Broker)

+44 (0)20 7220 0500

Geoff Nash / Kate Bannatyne / Alice Lane

Walbrook PR Ltd (Media Relations & Investor Relations)

+44 (0)20 7933 8780 or genedrive@walbrookpr.com

Paul McManus / Anna Dunphy

+44 (0)7980 541 893 / +44 (0)7876 741 001

 

 

About genedrive plc (http://www.genedriveplc.com)

 

genedrive plc is a molecular diagnostics company developing and commercialising a low cost, rapid, versatile, simple to use and robust point of need molecular diagnostics platform for the diagnosis of infectious diseases and for use in patient stratification (genotyping), pathogen detection and other indications. The Company has assays on market for the detection of HCV, certain military biological targets and a high throughput SARS-CoV-2 assay. The Company has also recently launched a test to help in the prevention of hearing loss caused by certain antibiotics in neonates.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BOAJFMATMTBBBBT
Date   Source Headline
4th Aug 20207:00 amRNSCollaboration to automate COVID-19 PCR testing
23rd Jul 202011:06 amRNSSecond Price Monitoring Extn
23rd Jul 202011:00 amRNSPrice Monitoring Extension
22nd Jul 20203:13 pmRNSHolding(s) in Company
21st Jul 202011:05 amRNSSecond Price Monitoring Extn
21st Jul 202011:00 amRNSPrice Monitoring Extension
16th Jul 20204:29 pmRNSHolding(s) in Company
13th Jul 20209:00 amRNSPrice Monitoring Extension
10th Jul 20202:05 pmRNSSecond Price Monitoring Extn
10th Jul 20202:00 pmRNSPrice Monitoring Extension
10th Jul 20207:01 amRNSNew Genedrive® 96 Exporter software
10th Jul 20207:00 amRNSTrading update
1st Jul 20207:00 amRNSTotal Voting Rights
26th Jun 20203:24 pmRNSHolding(s) in Company
25th Jun 20203:39 pmRNSHolding(s) in Company
22nd Jun 20203:06 pmRNSHolding(s) in Company
22nd Jun 202011:08 amRNSHolding(s) in Company
18th Jun 202011:06 amRNSSecond Price Monitoring Extn
18th Jun 202011:00 amRNSPrice Monitoring Extension
17th Jun 20204:41 pmRNSSecond Price Monitoring Extn
17th Jun 20204:35 pmRNSPrice Monitoring Extension
17th Jun 20202:05 pmRNSSecond Price Monitoring Extn
17th Jun 20202:00 pmRNSPrice Monitoring Extension
16th Jun 202011:37 amRNSConversion of Convertible Bond
15th Jun 20204:40 pmRNSSecond Price Monitoring Extn
15th Jun 20204:36 pmRNSPrice Monitoring Extension
10th Jun 20207:00 amRNSInvestor presentation
9th Jun 20204:41 pmRNSSecond Price Monitoring Extn
9th Jun 20204:36 pmRNSPrice Monitoring Extension
9th Jun 20202:06 pmRNSSecond Price Monitoring Extn
9th Jun 20202:00 pmRNSPrice Monitoring Extension
9th Jun 202011:05 amRNSSecond Price Monitoring Extn
9th Jun 202011:00 amRNSPrice Monitoring Extension
29th May 20203:02 pmRNSHolding(s) in Company
29th May 202012:19 pmRNSHolding(s) in Company
29th May 202011:49 amRNSHolding(s) in Company
29th May 20208:30 amRNSHolding(s) in Company
28th May 20202:06 pmRNSSecond Price Monitoring Extn
28th May 20202:01 pmRNSPrice Monitoring Extension
28th May 20201:18 pmRNSApplication for Block Listing
28th May 202012:50 pmRNSHolding(s) in Company
28th May 202011:05 amRNSSecond Price Monitoring Extn
28th May 202011:00 amRNSPrice Monitoring Extension
27th May 202011:35 amRNSResult of General Meeting
27th May 20208:15 amRNSHolding(s) in Company
26th May 202011:58 amRNSHolding(s) in Company
26th May 20209:30 amRNSHolding(s) in Company
22nd May 202011:05 amRNSSecond Price Monitoring Extn
22nd May 202011:00 amRNSPrice Monitoring Extension
22nd May 20209:05 amRNSSecond Price Monitoring Extn

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.